AstraZeneca should stick to its winning formula. It doesn’t need a $400bn US mega-merger
The Anglo-Swedish drugmaker’s flirtation with a grand combo with US group Bristol Myers Squibb is baffling • AstraZeneca shares fall 8.9% over merger talks with US cancer drug firm Sir Pascal Soriot, chief executive of AstraZeneca, starts with huge credit in the bank, obviously. His long tenure has been a triumph, starting with the against-the-odds victory over Pfizer’s charmless accountants in…
We haven't written up this one. Guardian Business has the full story — the link below goes straight to it.
